Limited Distribution Deals Confirmed

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).

Here are several Limited Distribution deals that have been recently publicly confirmed subsequent to the approvals.

AllianceRx Walgreens Prime
Cancer-fighting Lenvima Available Through AllianceRx Walgreens Prime
May 18, 2022—Patients of AllianceRx Walgreens Prime who have certain kinds of cancer will now have access to Lenvima (lenvatinib), newly available via limited distribution.

Manufactured by Eisai Inc., Lenvima is used by itself to treat differentiated thyroid cancer (DTC) and hepatocellular carcinoma (HCC). DTC is a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing. HCC is a type of liver cancer, for which Lenvima is a first-line treatment when surgery is not an option. Lenvima also treats advanced renal cell carcinoma, a type of kidney cancer, when used in conjunction with another anti-cancer medicine. Patients with certain types of advanced endometrial carcinoma may also use Lenvima when used in combination with another anticancer medication.

Soleo Health
Named to Genentech’s Limited Drug Distribution Network for Provision of ENSPRYNG
Company to Distribute FDA-Approved Treatment for Neuromyelitis Optica Spectrum Disorder
Soleo Health announced today it has been named a limited distribution drug partner for ENSPRYNG (satralizumab-mwge), from Genentech. ENSPRYNG is indicated for Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare autoimmune disease of the optic nerve, brain and spinal cord, who are anti-aquaporin-4 (AQP4) antibody positive. ENSPYRNG is a subcutaneous treatment administered every four weeks.

Soleo Health Named as Distribution Partner by Mitsubishi Tanabe Pharma for RADICAVA ORS
Soleo Health announced today it was named one of only four limited distribution drug (LDD) specialty pharmacy partners to dispense nationwide RADICAVA ORS (edaravone) oral suspension, commercialized by Mitsubishi Tanabe Pharma America, Inc. (MTPA).

The FDA approved the oral formulation of edaravone on May 12, 2022. RADICAVA ORS is among a select few FDA-approved oral treatments for patients with Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disorder. Edaravone is also approved in an intravenous (IV) formulation, known as RADICAVA® (edaravone). Soleo Health has been a limited distribution partner for the infused form since launch in 2017.

Onco360
ORGOVYX (relugolix) Now Available from Onco360 for the Treatment of Advanced Prostate Cancer
Onco360, the nation’s leading independent Specialty Pharmacy, has been named as a limited distribution specialty pharmacy partner for ORGOVYX (relugolix), a gonadotropin-releasing hormone (GnRH) antagonist that is approved by the FDA for the treatment of adult patients with advanced prostate cancer. ORGOVYX ® is commercialized by Myovant Sciences, Inc. and Pfizer, Inc.

Share:

Read More

US Bioservices Acquired by CVS

The word on the street is that CVS has acquired US Bioservices from AmerisourceBergen….. and it seems that CVS is treating it as a closely

Send Us A Message

This website uses cookies to ensure you get the best experience on our website.